- US-listed companies
- Viridian Therapeutics, Inc.DE
- Income statement
Viridian Therapeutics, Inc.DE (VRDN) Income statement
Market cap
$1.5B
P/E ratio
| 2014/12 | 2015/12 | 2016/12 | 2017/12 | 2018/12 | 2019/12 | 2020/12 | 2021/12 | 2022/12 | 2023/12 | 2024/12 | 2025/12 | |
| Revenue | 4 | 3 | 3 | 4 | 8 | 4 | 1 | 3 | 2 | 0 | 0 | 71 |
| Revenue growth (%) | - | |||||||||||
| Cost of revenue | 3 | 2 | 3 | - | - | - | - | - | - | - | - | - |
| Research & development | 0 | 1 | 1 | 20 | 30 | 35 | - | - | - | - | - | - |
| Selling, general & administrative | - | - | - | - | - | - | - | - | - | - | - | 95 |
| Operating margin (%) | ||||||||||||
| Operating expenses | 11 | 14 | 16 | 31 | 41 | 46 | 111 | 83 | 136 | 255 | 299 | 434 |
| Operating income | -7 | -11 | -13 | -27 | -33 | -42 | -110 | -80 | -134 | -254 | -299 | -363 |
| Net income | -8 | -11 | -13 | -27 | -33 | -42 | -111 | -79 | -130 | -238 | -270 | -343 |
| Net income margin (%) | ||||||||||||
| Earnings per share | - | - | - | - | - | - | - | -6.66 | -4.05 | -5.31 | - | - |
| Diluted EPS | - | - | - | - | - | - | - | -6.66 | -4.05 | -5.31 | - | - |
| EBITDA | ||||||||||||
| EBITDA margin (%) |